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Statement of Translational Relevance: (max 150 words; currently 143)
Aurora A Kinase (AAK) has been implicated in oncogenesis and tumor progression, and is amplified or overexpressed in several tumor types. In this article we describe the development of three novel biomarker assays of AAK activity that provide detailed and specific information regarding the biological effects of AAK inhibition in vivo. The novel assays therefore provide a basis for translating the mechanism of action of AAK inhibitors into clinically informative pharmacodynamic endpoints. In conjunction with established methods, these assays were used to describe the in vitro and in vivo antitumor activity of an investigational AAK inhibitor, alisertib (MLN8237). Our data indicate that alisertib is a selective and potent inhibitor of AAK, and supports its continued clinical development as an anticancer agent. Furthermore, the assays described here are currently being deployed in phase I studies to help characterize the activity of alisertib in patients.
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Introduction
Mitotic kinases, kinesins and other mitotic enzymes are being pursued as targets for the next generation of antimitotic therapies in oncology. While several molecules have demonstrated clinical efficacy, it is too early to know if they will add benefit beyond classic microtubule antagonists such as the taxanes and vinca alkaloids. So far however, it is clear that the newer agents are unlikely to cause the peripheral neuropathy often observed in patients treated with microtubule-targeting drugs (1) .
The conventional view of antimitotic agents is that they cause prolonged mitotic arrest leading to cell death. In recent years, this perspective has been modified to incorporate two alternative outcomes following mitotic delays in metaphase (2, 3) . Studies using live-cell microscopy with a variety of antimitotic agents in a range of cell lines have reported a striking diversity of responses (4) (5) (6) . In some sensitive cell lines, mitotic arrest is sustained until cells die directly from prometaphase. In other sensitive cell lines, the mitotic delay is transient, and is followed by an inappropriate segregation of unaligned chromosomes (4, 5, 7) . This mitotic slippage is followed by a variety of terminal outcomes that appear to include post-mitotic death as well as terminal growth arrest (cellular senescence) (8, 9) . Evidence exists to support the view that cytostasis (10, 11) , as well as post-mitotic cell death (5) The complex mechanism of action of antimitotic agents has posed a significant challenge for the development of pharmacodynamic biomarkers for their action. The obvious and traditional biomarker, the mitotic index, is hampered by the cell-line-to-cell-line differences in the duration of mitotic arrest (4, 5) , and by the tendency of low concentrations of antimitotic agents to reduce cellular viability without a prolonged mitotic arrest, via a mitotic slippage-based mechanism (12, 13) . Surprisingly, even within the same cell type, there is often a diversity of responses to the same mitotic inhibitor at different concentrations (4, 5, 13) , and heterogeneity in the degree of mitotic arrest versus mitotic slippage within the same population of cells (4, 5) . Consistent with these findings, the length of mitotic arrest within in a given cell type has been found not to correlate with probability of death (4, 5) .
This weak linkage between mitotic arrest and cell death provides us with a retrospective explanation for the failure of early attempts to use the mitotic index to provide guidance for taxane development. For these agents, preclinical in vivo work showed minimal (14) or nonexistent (15) predictive value for mitotic index with respect to anticipating the degree of tumor growth inhibition, which was later corroborated in patient tumor biopsies (16) . Aurora A and Aurora B are related serine/threonine kinases that share significant sequence similarity but differ in their localization, substrate specificity, and function. The function of these kinases has been reviewed extensively (17- (23) (24) (25) (26) (27) .
Although inhibition of Aurora kinases can alter the microtubule network, (7) a potentially unique feature that may distinguish Aurora kinase inhibitors from the microtubule antagonists as anticancer agents is the additional regulatory functions the Aurora kinases play. For example, Aurora A directly binds to and regulates the turnover of N-myc, and may be essential in N-myc amplified neuroblastomas (28) . In addition, both Aurora A and Aurora B have been shown to phosphorylate and regulate p53 function in experimental systems (29, 30) .
Determining which of these additional functions are most important for tumor survival should provide insights into patient stratification strategies or rational combination approaches.
Inhibition of Aurora A kinase leads to the formation of mitotic spindle defects and misaligned chromosomes (7, 31, 32) . However, despite these mitotic defects, cells lacking functional Aurora A often divide, albeit abnormally (7, 33) .
Research. -11-1536 This inappropriate division in the presence of spindle defects appears to be the result of compromised spindle assembly checkpoint function (34) . The abnormal mitotic divisions result in deleterious aneuploidy and chromosomal instability leading to cell death or arrest (7) . However, a portion of cells can recover from these outcomes and can reenter the cell cycle. The alternative fates subsequent to post-mitotic defects induced by Aurora A and Aurora B kinase inhibition are mediated in part by the p53 and p73 signaling pathways (35, 36) . Additionally, Aurora A inhibition in a range of cell types has been demonstrated to lead to a reduction in the rate of mitotic entry due to a late G2 block in the cell cycle (37) (38) (39) (40) . As is the case for traditional antimitotic agents, this complexity in the downstream cell biological consequences of Aurora A inhibition has led to challenges in the use of the mitotic index as a pharmcodynamic measurement in tumors. In particular, we have previously shown that the mitotic index is an early marker of Aurora A inhibition (32), which decays gradually over time due to a loss of the cycling population of cells.
To address these limitations in the use of mitotic index in drug development, we developed three novel assays to quantitatively measure biomarkers of Aurora A inhibition in vivo. The first two assays, as reported intially 
Material and Methods
Enzyme and cell-based assays to measure kinase inhibition. Aurora A and Aurora B radioactive Flashplate ® enzyme assays and cell-based assays were conducted to determine the nature and degree of alisertib-mediated inhibition in vitro, as described by Manfredi et al (32) . In the cell-based assays, Aurora A activity was determined by measuring autophosphorylation of Aurora A on threonine 288, while Aurora B activity was determined by measuring phosphorylation of histone H3 on Serine 10 (pHisH3), in both cases using high content imaging assays, and as previously described (32) . The inhibitory activity of 1 µM alisertib was also tested against 205 kinases (SelectScreen™ kinase panel, Invitrogen, Carlsbad, CA). Mice bearing HCT-116 xenografts were treated orally with a single dose of 3, 10, and 30 mg/kg alisertib, and tumor samples were removed at specified time points.
Frozen tumor tissue sections were stained for the mitotic marker pHisH3 then visualized using immunofluorescence detection, and quantified at the indicated time-points. The methods used to stain and quantify pHisH3, which is also an Aurora B substrate, have been described previously (32) . Aurora B inhibition would result in a decrease in pHisH3, while Aurora A inhibition would result in an increase in the mitotic marker (32) . For chromosome alignment and spindle bipolarity assays, tumor samples were harvested from mice bearing HCT-116 xenograft tumors at specified time points, then formalin fixed and paraffin embedded. The samples were sectioned at 5 μm and stained using the analyzed as the standardized uptake value (SUV) of the VOI, SUV VOI , and was normalized to baseline.
Results
In vitro studies show that alisertib inhibits Aurora A kinase and is selective over family member Aurora B kinase and other kinases. Alisertib has a benzazepine core structure with a fused amino pyrimidine ring and an aryl carboxylic acid (Supplementary Fig. 1 ). In enzymatic assays, alisertib was a potent inhibitor of Aurora A kinase, with an IC 50 value of 1.2 nM (Table 1) .
Alisertib has less activity against Aurora B kinase with an IC 50 value of 396.5 nM in enzymatic assay. The cell-based assays demonstrated that alisertib was at least 200-fold more selective for Aurora A (IC 50 = 6.7 nM) than Aurora B (IC 50 = 1534 nM) (Supplementary Fig. 2 ). In addition, alisertib demonstrated selectivity in enzymatic assays against a 205-kinase panel (Supplementary Fig. 3 ).
Phenotypic cell-based assays supported the selectivity of alisertib for Aurora A kinase over Aurora B kinase. At a concentration of 0.050 µM alisertib, cell-cycle analysis using flow cytometry demonstrated an increase in cells in the G2/M phase at 24 and 48 hrs (Fig. 1A) , a phenotype consistent with Aurora A inhibition (7, 32) . In addition, cells treated at this concentration displayed mitotic spindle abnormalities and chromosome misalignment (Fig. 1B) , phenotypes that were previously described to be associated with Aurora A inhibition (7 phenotypes consistent with Aurora B inhibition. At these concentrations cell-cycle analysis showed an increase in the number of cells with 8N DNA content (Fig. 1A) . In addition, immunofluoresent staining of chromosomes and α-tubulin suggested that these cells are multinucleated (Fig. 1B) . 
Alisertib inhibits proliferation
Aurora A kinase in vivo ( Supplementary Fig. 4 ). Moreover, there was no inhibition of pHisH3 at concentrations of approximately 6 μM demonstrating a significant selectivity for Aurora A inhibition over Aurora B in vivo.
To further characterize the in vivo phenotype of Aurora A inhibition, tumors treated with alisertib at the doses used above were assessed for chromosome alignment and mitotic spindle defects. In order to assess mitotic tumor cells for chromosome alignment and spindle bipolarity, sections were stained for α-tubulin strong reduction in chromosome alignment and spindle bipolarity in the first 4 hrs (Fig 2C and D) , followed by partial recovery of chromosome alignment and spindle bipolarity by 8 hrs. The effects observed in the 3 mg/kg dose group were more modest, with a partial reduction of chromosomal alignment and bipolarity at 4 hrs, followed by substantial recovery in chromosomal alignment by 8 hrs.
Taken together, alisertib at all three doses exhibited phenotypes that were consistent with Aurora A inhibition. Aurora A when both kinases are inhibited. Taken together, these data demonstrates a selectivity window of alisertib for Aurora A kinase over Aurora B kinase in enzyme and cell-based assays.
We used novel in vivo assays assessing quantitative spindle bipolarity and chromosome alignment to monitor Aurora A activity in vivo. These assays demonstrated that at the MTD in mice, alisertib treatment reduced spindle bipolarity and increased chromosome misalignment. Our findings indicate that by 8 hrs, spindle bipolarity but not chromosomal alignment had partially recovered in the 30 mg/kg dose group, and that the majority of spindles in this dose group were bipolar, with misaligned chromosomes. These results are consistent with the findings reported by us as well as others in cell culture (7, 33, 41, 46) and suggests that Aurora A inhibition leads to transient mitotic arrest followed by inappropriate passage through anaphase in the presence of misaligned chromosomes.
The transient nature and slow onset of the mitotic delays that occur with Aurora A inhibition led us to investigate these alternative mechanism-based pharmacodynamic biomarkers with a more rapid onset than the mitotic index. It is interesting to note that there is a substantial difference in time between peak mitotic index (8 to 12 hrs; Fig. 2A ) compared to the peak changes in the chromosome alignment and spindle bipolarity assays (1 hr; Fig. 2C and D) . One potential explanation for this is that the mitotic index assay, which measures the 
fraction of mitotic cells in the entire population, requires several hours to accumulate mitotic cells, whereas the spindle bipolarity/chromosomal alignment assays focus on cells that are currently in mitosis, where the loss of mitotic spindle integrity upon Aurora A inhibition is rapid. An alternative explanation for the difference in kinetics between the mitotic index and the spindle bipolarity/chromosome alignment assays is the previously described role for Aurora A in mitotic commitment. Such a reduction in the rate of mitotic entry would be consistent with the delayed increase in the mitotic index observed with Aurora A inhibition.
Aurora A inhibition results in a delayed mitosis followed by an abnormal cellular division. One commonly reported outcome of Aurora A inhibition is a postmitotic p53-dependent G1 arrest (47) , that in some cases has been shown to lead to apoptosis. Cellular senescence has also been demonstrated to be a longterm effect of Aurora A inhibition in vitro and in vivo (8) .
Using markers of S-phase, BrdU, which gets incorporated into DNA, and FLT, which is phosphorylated and trapped in cells by the S-phase active thymidine kinase 1, we detected an inhibition of proliferation in vitro and in vivo.
In both cases alisertib reduced the number of cells in S-phase. This could be due to transient mitotic delay, consistent with a pharmacodynamic effect of Aurora A inhibition, or due to cells undergoing apoptosis or cellular senescence. Inhibition of proliferation by Aurora A inhibition has been shown to be mediated by two known terminal outcomes including apoptosis and cellular senescence (8, 32) .
For the in vivo study, there was an initial decrease in FLT uptake followed by a gradual decline to day 21. We have previously shown with MLN8054, another Aurora A inhibitor similar to alisertib, that cells continue to divide for several divisions over the first few days following AurA inhibition (7), and undergo apoptosis as well as cell-cycle arrest during this period. This suggests that the initial decrease in FLT may not be due to senescence but rather apoptosis or the initial activation of the p53-dependent G1 arrest. However, at later timepoints the decrease in FLT may be due to cellular senescence, as we have previously demonstrated; senescence, as detected by beta galactosidase staining, does not set in until day 15 and is maximal at day 21 (8) .
Taken together, our data demonstrate that alisertib is a selective and potent inhibitor of Aurora A kinase. In addition, we have developed novel pharmacodynamic assays to assess Aurora A target inhibition in the clinic. To this end, the spindle bipolarity and chromosome alignment assays are currently being deployed on patient skin and tumor biopsies in phase I clinical trials. This data also suggests that FLT PET may be a valid non-invasive modality to understand multiple mechanisms of Aurora A inhibition including cellular senescence.
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